The specter of generic competition has repeatedly loomed around copyright’s blockbuster drug, PDE5 Inhibitor, raising questions about the prospects of connected drug ventures. While early years saw significant profits, the intellectual property expiration has opened the path for less expensive copies, potentially lowering earnings and posing a si